Jun 2026 (Q2 FY26) — Jul 28, 2026
Repligen Q2 FY26 — Strong Organic Growth and Raised Full-Year Outlook
Read the full callRepligen (RGEN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Repligen earnings: last reported Tue, 28 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 204 | +11.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 6.8 | −0.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 5.0 | −66.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
20 of 22 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| China regional revenue return to growth | back to growth mode around the second half of 2025 | Dec 2024 | China is a great turnaround for us this year. I mean in fact, first half, China grew more than 60%, which we're very, very delighted about. | Achieved |
| Full-year adjusted diluted EPS | $1.93 to $2.01 | Dec 2025 | we expect adjusted fully diluted earnings per share to be between $2.03 and $2.09, this is up $0.32 to $0.38 versus 2025 or up 20% at the midpoint. The midpoint reflects a $0.05 increase from our prior guidance. | Revised Up |
| Full-year adjusted gross margin expansion | 53.6% to 54.1%, approximately 125 basis points of expansion | Dec 2025 | We continue to expect 110 to 160 basis points of gross margin expansion for the year. | On Track |
2 of REPLIGEN CORP's 47 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 44 more targets are in the full ledger.
Claimed
- Achieved 13% organic revenue growth in Q2 FY26, driven by strong recurring revenue across the portfolio.
- Proteins franchise grew an impressive 50% in Q2 FY26, with Analytics growing over 30%.
- Adjusted operating margin expanded by 460 basis points to 16.7% in Q2 FY26.
- APAC revenue grew approximately 40% in Q2 FY26, with North America growing high teens.
- Raised full-year 2026 organic revenue growth guidance by 1 percentage point at the midpoint and adjusted EPS guidance by $0.05.
Qualified
- Filtration revenue grew only slightly in Q2 FY26 due to headwinds from Polymem sale, gene therapy program, and ATF customer inventory management/site delays.
- EMEA revenue declined mid-single digits in Q2 FY26 due to a difficult prior year comparison.
- Capital equipment revenue declined slightly year-over-year in Q2 FY26, though orders picked up sequentially.
Price
$184.17 +3.35% · +$5.97
Performance +24.1% 1Y
1Y: $148.4 on 14 Oct 2025 → $184.17. High $194.57 (29 Sept 2026), low $102.87 (15 May 2026).
- Previous close
- $178.2
- 52-week range
- $102.87 – $194.57
- One year
- +23.17%
Overview
- Symbol
- RGEN
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
20 of 22 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| China regional revenue return to growth | back to growth mode around the second half of 2025 | Dec 2024 | China is a great turnaround for us this year. I mean in fact, first half, China grew more than 60%, which we're very, very delighted about. | Achieved |
| Full-year adjusted diluted EPS | $1.93 to $2.01 | Dec 2025 | we expect adjusted fully diluted earnings per share to be between $2.03 and $2.09, this is up $0.32 to $0.38 versus 2025 or up 20% at the midpoint. The midpoint reflects a $0.05 increase from our prior guidance. | Revised Up |
| Full-year adjusted gross margin expansion | 53.6% to 54.1%, approximately 125 basis points of expansion | Dec 2025 | We continue to expect 110 to 160 basis points of gross margin expansion for the year. | On Track |
Claimed
- Achieved 13% organic revenue growth in Q2 FY26, driven by strong recurring revenue across the portfolio.
- Proteins franchise grew an impressive 50% in Q2 FY26, with Analytics growing over 30%.
- Adjusted operating margin expanded by 460 basis points to 16.7% in Q2 FY26.
- APAC revenue grew approximately 40% in Q2 FY26, with North America growing high teens.
- Raised full-year 2026 organic revenue growth guidance by 1 percentage point at the midpoint and adjusted EPS guidance by $0.05.
Qualified
- Filtration revenue grew only slightly in Q2 FY26 due to headwinds from Polymem sale, gene therapy program, and ATF customer inventory management/site delays.
- EMEA revenue declined mid-single digits in Q2 FY26 due to a difficult prior year comparison.
- Capital equipment revenue declined slightly year-over-year in Q2 FY26, though orders picked up sequentially.
The full ledger
Open REPLIGEN CORP’s full ledger
A free account opens 5 company ledgers a month. All 47 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Repligen Q1 FY26 — Strong Organic Growth and Margin Expansion, Strategic Initiatives Progress
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Repligen Q4 FY25 — Robust Organic Growth and Margin Expansion
Read the full callEvery analysed call
Repligen earnings calls (RGEN)
Financials
What the filings say
Net profit, year on year: −66% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 155 | 168 | 169 | 182 | 189 | 198 | 194 | 204 |
| Expenses | 163 | 204 | 163 | 168 | 172 | 180 | 178 | 190 |
| Operating profit | -8 | -37 | 7 | 14 | 17 | 18 | 16 | 14 |
| Operating margin | −5.1% | −21.8% | 3.9% | 7.6% | 8.9% | 9.0% | 8.2% | 6.8% |
| Other income | 7 | -2 | 1 | 4 | 0 | 1 | -14 | 0 |
| Interest | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | -1 | -39 | 8 | 18 | 17 | 19 | 2 | 14 |
| Tax rate | 43.1% | 12.3% | 26.6% | 18.4% | 12.9% | 30.5% | −370.3% | 64.6% |
| Net profit | -1 | -34 | 6 | 15 | 15 | 13 | 8 | 5 |
| EPS ($ per share) | -0.01 | — | 0.10 | 0.26 | 0.27 | — | 0.15 | 0.09 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -1 | 6 | 66 | 194 | 397 | 433 | 407 | 456 |
| Total liabilities | 159 | 340 | 374 | 608 | 621 | 866 | 857 | 844 |
| Fixed assets | 32 | 48 | 67 | 125 | 191 | 207 | 198 | 187 |
| Investments | 0 | — | — | — | — | — | 0 | 202 |
| Total assets | 775 | 1,400 | 1,903 | 2,358 | 2,532 | 2,831 | 2,830 | 2,950 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 33 | 67 | 63 | 119 | 172 | 114 | 175 | 117 |
| Cash from investing | -14 | -205 | -201 | -221 | -233 | -123 | -86 | -298 |
| Cash from financing | 3 | 485 | 306 | 1 | -13 | 249 | -83 | -15 |
| Net cash flow | 20 | 344 | 180 | -113 | -80 | 228 | 6 | -191 |
| Capital expenditure | -11 | -19 | -22 | -67 | -85 | -36 | -26 | -24 |
| Free cash flow | 22 | 49 | 40 | 52 | 87 | 78 | 150 | 94 |
RGEN revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Product | 100% | — | 100% | 100% | 100% | — | 100% | 100% | +11.9% |
| Royalty | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | +16.2% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
69 filings between Nov 12, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$15.26M
25 sales by 5 insiders
64% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 9
- Option exercise — converted options into shares
- 17
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Loeillot Olivier | — | $7.69M | Oct 5, 2026 |
| Hunt Anthony | — | $7.01M | Nov 13, 2025 |
| Bylund James | — | $331.3K | Nov 18, 2025 |
| Garland Jason K | — | $185.8K | Jul 16, 2026 |
| DAWES KAREN A | — | $44.3K | Dec 17, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Award | 700 | $0 |
| Oct 5, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 4,202 | $798.4K |
| Oct 5, 2026 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 plan | 4,202 | $651.1K |
| Oct 5, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 1,333 | $238.3K |
| Oct 2, 2026 | Loeillot Olivier Chief Executive Officer | Tax withheld | 1,248 | $226.8K |
| Sep 25, 2026 | Garland Jason K CFO | Tax withheld | 421 | $79.9K |
| Sep 24, 2026 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 plan | 4,542 | $705.7K |
| Sep 24, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 4,542 | $863.0K |
| Sep 24, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 8,404 | $1.60M |
| Sep 24, 2026 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 plan | 8,404 | $1.30M |
| Sep 21, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 5,426 | $976.7K |
| Sep 21, 2026 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 plan | 5,426 | $769.4K |
| Sep 4, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 3,035 | $503.5K |
| Sep 3, 2026 | Loeillot Olivier Chief Executive Officer | Tax withheld 10b5-1 plan | 2,842 | $482.0K |
| Sep 1, 2026 | Hughes Violetta CHIEF ACCOUNTING OFFICER | Tax withheld | 277 | $47.1K |
| Aug 20, 2026 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 plan | 5,426 | $769.4K |
| Aug 20, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 5,426 | $976.7K |
| Jul 16, 2026 | Garland Jason K CFO | Sale 10b5-1 plan | 530 | $79.5K |
| Jun 25, 2026 | Garland Jason K CFO | Sale 10b5-1 plan | 733 | $106.3K |
| May 14, 2026 | BARTHELEMY NICOLAS Director | Award | 995 | $0 |
| May 14, 2026 | Pax Margaret Director | Award | 995 | $0 |
| May 14, 2026 | Konstantinov Konstantin Director | Award | 995 | $0 |
| May 14, 2026 | DAWES KAREN A Director | Award | 995 | $0 |
| May 14, 2026 | Madaus Martin D Director | Award | 995 | $0 |
| May 14, 2026 | EGLINTON MANNER CARRIE Director | Award | 995 | $0 |
| May 14, 2026 | MUIR GLENN P Director | Award | 995 | $0 |
| May 14, 2026 | Mhatre Rohin Director | Award | 995 | $0 |
| May 7, 2026 | MUIR GLENN P Director | Option exercise | 2,434 | $94.3K |
| May 7, 2026 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Tax withheld | 334 | $42.2K |
| Apr 21, 2026 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 plan | 3,832 | $536.5K |
| Mar 5, 2026 | Hughes Violetta CHIEF ACCOUNTING OFFICER | Award | 2,466 | $0 |
| Mar 5, 2026 | Garland Jason K CFO | Award | 7,751 | $0 |
| Mar 5, 2026 | Bylund James Chief Operating Officer | Award | 7,751 | $0 |
| Mar 5, 2026 | KURIYEL RALF Senior VP, R&D | Award | 5,284 | $0 |
| Mar 5, 2026 | Loeillot Olivier Chief Executive Officer | Award | 24,134 | $0 |
| Mar 4, 2026 | KURIYEL RALF Senior VP, R&D | Award | 125 | $0 |
| Mar 4, 2026 | Bylund James Chief Operating Officer | Tax withheld | 62 | $7.8K |
| Mar 4, 2026 | Bylund James Chief Operating Officer | Award | 125 | $0 |
| Mar 4, 2026 | KURIYEL RALF Senior VP, R&D | Tax withheld | 42 | $5.3K |
| Mar 2, 2026 | Loeillot Olivier Chief Executive Officer | Tax withheld | 1,610 | $201.2K |
| Mar 2, 2026 | Garland Jason K CFO | Tax withheld | 715 | $89.4K |
| Mar 2, 2026 | Hunt Anthony Director | Tax withheld | 9,897 | $1.24M |
| Mar 2, 2026 | KURIYEL RALF Senior VP, R&D | Tax withheld | 923 | $115.3K |
| Mar 2, 2026 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Tax withheld | 221 | $27.6K |
| Mar 2, 2026 | Bylund James Chief Operating Officer | Tax withheld | 2,433 | $304.1K |
| Feb 27, 2026 | Loeillot Olivier Chief Executive Officer | Tax withheld | 344 | $44.3K |
| Feb 27, 2026 | Garland Jason K CFO | Tax withheld | 327 | $42.1K |
| Feb 27, 2026 | KURIYEL RALF Senior VP, R&D | Tax withheld | 444 | $57.2K |
| Feb 27, 2026 | Bylund James Chief Operating Officer | Tax withheld | 1,478 | $190.3K |
| Dec 31, 2025 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Award | 2,288 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for REPLIGEN CORP
Free account. Everything above stays public.
Write why you follow REPLIGEN CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading